Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris
Standard
Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. / Maurer, P; Sandulescu, T; Kriwalsky, M S; Rashad, A; Hollstein, S; Stricker, I; Hölzle, F; Kunkel, M.
in: INT J ORAL MAX SURG, Jahrgang 40, Nr. 3, 03.2011, S. 285-91.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris
AU - Maurer, P
AU - Sandulescu, T
AU - Kriwalsky, M S
AU - Rashad, A
AU - Hollstein, S
AU - Stricker, I
AU - Hölzle, F
AU - Kunkel, M
N1 - Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
PY - 2011/3
Y1 - 2011/3
N2 - Bisphosphonates (BPs) are widely used as bone-stabilizers, but side effects of BP therapy include bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is resistant to therapy. The aim of this study was to evaluate the outcome of maxillary BRONJ involving sinusitis maxillaris. 21 patients presenting with maxillary BRONJ, from 2005 to 2008, were included in the study. In 18 cases BP had been administered for carcinoma and in 3 cases for osteoporosis, with an average exposure time of 47.4 months. 12 patients spontaneously developed BRONJ. The 10 patients diagnosed with stage III BRONJ presented with concomitant sinusitis maxillaris. Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris. Whether BRONJ occurred spontaneously or after extraction there was no difference in the outcome. Patients with advanced maxillary BRONJ often suffer from sinusitis maxillaris, both of which are frequently resistant to therapy.
AB - Bisphosphonates (BPs) are widely used as bone-stabilizers, but side effects of BP therapy include bisphosphonate-related osteonecrosis of the jaw (BRONJ), which is resistant to therapy. The aim of this study was to evaluate the outcome of maxillary BRONJ involving sinusitis maxillaris. 21 patients presenting with maxillary BRONJ, from 2005 to 2008, were included in the study. In 18 cases BP had been administered for carcinoma and in 3 cases for osteoporosis, with an average exposure time of 47.4 months. 12 patients spontaneously developed BRONJ. The 10 patients diagnosed with stage III BRONJ presented with concomitant sinusitis maxillaris. Despite treatment, there were six recurrences of BRONJ, four of them with additional sinusitis maxillaris. Whether BRONJ occurred spontaneously or after extraction there was no difference in the outcome. Patients with advanced maxillary BRONJ often suffer from sinusitis maxillaris, both of which are frequently resistant to therapy.
KW - Aged
KW - Aged, 80 and over
KW - Amoxicillin-Potassium Clavulanate Combination
KW - Anti-Bacterial Agents
KW - Bone Density Conservation Agents
KW - Carcinoma
KW - Chronic Disease
KW - Debridement
KW - Diphosphonates
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Imidazoles
KW - Injections, Intravenous
KW - Male
KW - Maxillary Diseases
KW - Maxillary Sinusitis
KW - Middle Aged
KW - Osteonecrosis
KW - Osteoporosis
KW - Osteotomy
KW - Recurrence
KW - Risk Factors
KW - Time Factors
KW - Tomography, X-Ray Computed
KW - Treatment Outcome
KW - Zoledronic Acid
KW - Journal Article
U2 - 10.1016/j.ijom.2010.11.006
DO - 10.1016/j.ijom.2010.11.006
M3 - SCORING: Journal article
C2 - 21163624
VL - 40
SP - 285
EP - 291
JO - INT J ORAL MAX SURG
JF - INT J ORAL MAX SURG
SN - 0901-5027
IS - 3
ER -